Adbert Alzolay's comeback: Can he revive his career in the Mets' bullpen? The Mets are hoping for a bullpen boost from a pitcher with a fascinating journey. But can he overcome his injury-riddled past?
The Mets signed Alzolay, a right-handed pitcher, to a minor league deal in 2025, knowing he was recovering from Tommy John surgery. This procedure often requires a lengthy recovery, but the Mets had a plan for his return in 2026. Despite his absence from minor league games in 2025, Alzolay pitched in the Venezuelan Winter League, proving his health. And with no options left, he's poised to make an impact in spring training.
Alzolay's career began promisingly. He was ranked highly by Baseball Prospectus in 2018 and debuted with the Cubs in 2019. Over the next few seasons, he made sporadic appearances, battling injuries. In 2022, a right lat injury limited his playing time, but he returned as a multi-inning reliever. The following year, he thrived in this role, posting impressive stats: a 2.67 ERA and a 3.02 FIP in 64 innings.
However, 2024 was a different story. Alzolay struggled early on and was eventually sidelined by an elbow injury. And this is where it gets controversial: despite his injury, the Mets are betting on him to replicate his 2023 success. His walk rate was exceptional, but can he maintain that control? And will his strikeout rate be enough to make a difference?
The Mets' decision to sign Alzolay is reminiscent of their handling of Brooks Raley's recovery. While Raley's comeback was a success, can Alzolay follow suit? Projections suggest a modest return, but the Mets are aiming higher. They believe he can be a key piece in their bullpen puzzle.
What's your take on Adbert Alzolay's potential impact? Will he be a reliable reliever or face more setbacks? Share your thoughts in the comments, and let's discuss his journey and the Mets' strategy!
